Syngene International Limited — Updates, 10-03-2025: Press Release

Syngene International Limited has acquired its first biologics manufacturing facility in the USA, located in Baltimore, which includes multiple monoclonal antibody (mAbs) manufacturing lines. This strategic investment, totaling approximately USD 50 million, aims to enhance Syngene's global biologics footprint, catering to both human and animal health markets.

The facility increases single-use bioreactor capacity to 50,000L, augmenting existing capabilities across Syngene’s locations in India and North America. The acquisition is expected to generate local jobs, stimulate economic activity, and bolster domestic biologics manufacturing, while contributing to pharmaceutical innovation and strengthening supply chain resilience.

Syngene’s CEO highlighted the alignment of this facility with growing client demand in the US, underscoring its potential to provide a competitive edge in the fast-evolving biologics market. Despite anticipated short-term margin dilution due to initial operational costs, the asset is projected to achieve an asset turnover of 1x within five years, with EBIT margins returning to company averages by FY30.